Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio-Gate AGSTU:BIG 30 Buyback Yield % is -15.61 as of Jul. 31, 2026. GuruFocus rates STU:BIG with a GF Score™ of 30/100. The stock has 7 warning signs investors should review. Among 347 Medical Devices & Instruments companies, Bio-Gate AG ranks worse than 77.52% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Bio-Gate AG's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:BIG vs ISRG, BDX, MDLN: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, Bio-Gate AG's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Gate AG Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Gate AG's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Bio-Gate AG's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Gate AG (STU:BIG) has a Buyback Yield % of -15.61 as of Jul. 31, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bio-Gate AG and its competitors. According to the industry distribution chart, Bio-Gate AG ranks #269 out of 347 companies in the Medical Devices & Instruments industry, placing it in the top 77.5%.
Is Bio-Gate AG's Buyback Yield % too high?
Bio-Gate AG's current Buyback Yield % is -15.61. Based on the distribution chart, Bio-Gate AG ranks #269 out of 347 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bio-Gate AG has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Bio-Gate AG's Buyback Yield % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio-Gate AG ranks #269 out of 347 companies for Buyback Yield %. This places Bio-Gate AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Bio-Gate AG and its competitors. Bio-Gate AG's current Buyback Yield % is -15.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Gate AG stock overvalued right now?
Bio-Gate AG (STU:BIG) has a current Buyback Yield % of -15.61. The current Buyback Yield % is -15.61. Bio-Gate AG's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Bio-Gate AG (STU:BIG), the current Buyback Yield % is -15.61 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Gate AG is a Germany based medical technology company. The company employs silver technology to endow materials and products with antimicrobial properties. It is focused on the medical technology products portfolio. In addition, its technologies are also used to refine cosmetics, consumer goods, and industrial products. The products of the company are plasma-coating, additives, textile solutions, spray, masterbatches, and others. The organization uses two different technologies; first, silver particles are incorporated into cosmetics, paints, veneers or plastics, and second involve coating final products like implants or wound dressings with a silver-containing functional layer.
30GF Score
Get the complete analysis for STU:BIG
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:BIG has been successfully added to your 
